OxFORD Asset Management LLP Purchases New Holdings in Edwards Lifesciences Corporation (EW)

OxFORD Asset Management LLP purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 5,984 shares of the medical research company’s stock, valued at approximately $708,000.

Several other institutional investors also recently modified their holdings of EW. Dimensional Fund Advisors LP boosted its stake in Edwards Lifesciences Corporation by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 591,853 shares of the medical research company’s stock valued at $69,977,000 after acquiring an additional 4,014 shares during the last quarter. Virtu KCG Holdings LLC boosted its stake in Edwards Lifesciences Corporation by 88.6% in the second quarter. Virtu KCG Holdings LLC now owns 11,855 shares of the medical research company’s stock valued at $1,402,000 after acquiring an additional 5,569 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in Edwards Lifesciences Corporation by 48.6% in the second quarter. Parametric Portfolio Associates LLC now owns 518,160 shares of the medical research company’s stock valued at $61,267,000 after acquiring an additional 169,409 shares during the last quarter. WealthPLAN Partners LLC boosted its stake in Edwards Lifesciences Corporation by 253.8% in the second quarter. WealthPLAN Partners LLC now owns 2,300 shares of the medical research company’s stock valued at $272,000 after acquiring an additional 1,650 shares during the last quarter. Finally, Advisor Group Inc. boosted its stake in Edwards Lifesciences Corporation by 9.7% in the second quarter. Advisor Group Inc. now owns 18,935 shares of the medical research company’s stock valued at $2,124,000 after acquiring an additional 1,669 shares during the last quarter. 81.90% of the stock is owned by institutional investors and hedge funds.

EW has been the topic of a number of recent research reports. SunTrust Banks, Inc. raised their price objective on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Friday, June 30th. Canaccord Genuity reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Bank of America Corporation raised their price objective on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $120.75.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://ledgergazette.com/2017/10/17/oxford-asset-management-llp-purchases-new-holdings-in-edwards-lifesciences-corporation-ew.html.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 108.52 on Tuesday. The firm has a market capitalization of $22.91 billion, a price-to-earnings ratio of 32.91 and a beta of 0.62. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45. The company’s 50 day moving average is $111.37 and its 200-day moving average is $111.56.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. During the same period last year, the firm earned $0.76 earnings per share. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. Equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

In other Edwards Lifesciences Corporation news, VP Catherine M. Szyman sold 4,681 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The transaction was disclosed in a document filed with the SEC, which

Several other institutional investors also recently modified their holdings of EW. Dimensional Fund Advisors LP boosted its stake in Edwards Lifesciences Corporation by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 591,853 shares of the medical research company’s stock valued at $69,977,000 after acquiring an additional 4,014 shares during the last quarter. Virtu KCG Holdings LLC boosted its stake in Edwards Lifesciences Corporation by 88.6% in the second quarter. Virtu KCG Holdings LLC now owns 11,855 shares of the medical research company’s stock valued at $1,402,000 after acquiring an additional 5,569 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in Edwards Lifesciences Corporation by 48.6% in the second quarter. Parametric Portfolio Associates LLC now owns 518,160 shares of the medical research company’s stock valued at $61,267,000 after acquiring an additional 169,409 shares during the last quarter. WealthPLAN Partners LLC boosted its stake in Edwards Lifesciences Corporation by 253.8% in the second quarter. WealthPLAN Partners LLC now owns 2,300 shares of the medical research company’s stock valued at $272,000 after acquiring an additional 1,650 shares during the last quarter. Finally, Advisor Group Inc. boosted its stake in Edwards Lifesciences Corporation by 9.7% in the second quarter. Advisor Group Inc. now owns 18,935 shares of the medical research company’s stock valued at $2,124,000 after acquiring an additional 1,669 shares during the last quarter. 81.90% of the stock is owned by institutional investors and hedge funds.

EW has been the topic of a number of recent research reports. SunTrust Banks, Inc. raised their price objective on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Friday, June 30th. Canaccord Genuity reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Bank of America Corporation raised their price objective on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $120.75.

TRADEMARK VIOLATION NOTICE: This piece was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://ledgergazette.com/2017/10/17/oxford-asset-management-llp-purchases-new-holdings-in-edwards-lifesciences-corporation-ew.html.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 108.52 on Tuesday. The firm has a market capitalization of $22.91 billion, a price-to-earnings ratio of 32.91 and a beta of 0.62. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45. The company’s 50 day moving average is $111.37 and its 200-day moving average is $111.56.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. During the same period last year, the firm earned $0.76 earnings per share. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. Equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

In other Edwards Lifesciences Corporation news, VP Catherine M. Szyman sold 4,681 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The disclosure for this sale can be found here. Insiders sold 201,161 shares of company stock worth $22,826,072 over the last ninety days. Insiders own 2.13% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply